IMPACT
2018
Informing the Pathway of COPD Treatment
In 10,355 symptomatic COPD patients with ≥1 exacerbation per year, single-inhaler triple therapy (fluticasone furoate / umeclidinium / vilanterol) reduced moderate-or-severe exacerbations and mortality compared with the LAMA/LABA or LABA/ICS components.
Result
Primary endpoint: Annual rate of moderate or severe exacerbations
0.91 (triple) vs 1.07 (FF/VI; RR 0.85) and 1.21 (UMEC/VI; RR 0.75). Final all-cause mortality 1.20% vs 1.88% (HR 0.58; p=0.011) vs UMEC/VI.
- Subtopic
- Single-inhaler triple
- Design
- Multicentre RCT, 3-arm
- Relevance
- Important: one of several pillars.
- Cited in
- GOLD 2023 COPD
- Source
- Lipson DA, et al. N Engl J Med. 2018;378(18):1671-1680.doi 10.1056/NEJMoa1713901
Discussion & critique
Established single-inhaler triple therapy. ICS-withdrawal at randomisation in ~70% of the UMEC/VI arm may bias exacerbation and mortality results.